SS Innovations International (NASDAQ: SSII) has taken a significant step toward bringing its SSi Mantra surgical robotic system to the United States. The company announced it submitted a response on Oct. 5, 2026, to the U.S. Food and Drug Administration's request for additional information regarding its 510(k) submission for the SSi Mantra. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal.
The FDA is expected to complete its review of the response and the 510(k) submission in the first quarter of 2027. A favorable outcome would allow SS Innovations to introduce the SSi Mantra to the U.S. market, where it would compete with established surgical robotics players. The company's vision is to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the SSi Mantra system and the SSi Mudra suite of surgical instruments, which support a variety of procedures including cardiac surgery.
The SSi Mantra is a modular, multi-arm system featuring 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient-related information. It also offers superimposition of 3D models of diagnostic imaging and an optional tele-surgeon console called SSi MantrAsana, which provides telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.
For investors, the FDA submission represents a critical milestone. If approved, SS Innovations would gain access to the world's largest market for surgical robotics, potentially accelerating revenue growth and expanding its global footprint. The company, headquartered in India but a U.S. company, is focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. More information about SS Innovations can be found at ssinnovations.com or LinkedIn. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
The announcement was reported by TechMediaWire, a specialized communications platform focused on pioneering companies driving the future of technology. TechMediaWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. The full press release can be viewed at https://ibn.fm/A6dJ8.
